This is a promotional roadshow of meetings organised and funded by Angelini Pharma UK-I, and is intended for UK healthcare professionals only.
Hear how US and UK experts are using ONTOZRY® for the treatment of drug-resistant focal-onset seizures to help their epilepsy patients reach their goals.
ONTOZRY® is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.1
References:
1. ONTOZRY® Summary of Product Characteristics.
UK12063P | May 2022
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
UK Website
Prescribing Information and Adverse Event Reporting